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Enhanced NF-κB signaling in type-2 dendritic cells
at baseline predicts non-response to adalimumab
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Biologic therapies have transformed the management of psoriasis, but clinical outcome is
variable leaving an unmet clinical need for predictive biomarkers of response. Here we
perform in-depth immunomonitoring of blood immune cells of 67 patients with psoriasis,
before and during therapy with the anti-TNF drug adalimumab, to identify immune mediators
of clinical response and evaluate their predictive value. Enhanced NF-κBp65 phosphorylation,
induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlates
with lack of clinical response after 12 weeks of treatment. The heightened NF-κB activation is
linked to increased DC maturation in vitro and frequency of IL-17+ T cells in the blood of non-
responders before therapy. Moreover, lesional skin of non-responders contains higher
numbers of dermal DC expressing the maturation marker CD83 and producing IL-23, and
increased numbers of IL-17+ T cells. Finally, we identify and clinically validate LPS-induced
NF-κBp65 phosphorylation before therapy as a predictive biomarker of non-response to
adalimumab, with 100% sensitivity and 90.1% specificity in an independent cohort. Our study
uncovers important molecular and cellular mediators underpinning adalimumab mechanisms
of action in psoriasis and we propose a blood biomarker for predicting clinical outcome.
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Psoriasis is a common, chronic, immune-mediated, inflam-matory skin disease, affecting over 100 million peopleworldwide and is recognized as a serious non-
communicable disease by the World Health Organization for
the significant negative impact it has on people’s lives1.
Painful, disfiguring and disabling skin lesions result from the
combination of genetic susceptibility, environmental triggers and
dysregulated immune responses involving dendritic cells (DC),
IL-17-producing T (IL17+ T) cells, keratinocytes, and pro-
inflammatory cytokines2,3. Over the last two decades, significant
advances in understanding the pathogenic mechanisms under-
pinning psoriasis, have led to the adoption of biological treat-
ments (“biologics”) targeting the key cytokines TNF, IL-23 and
IL-17A, which have transformed disease management. Never-
theless, response to biologics is often heterogeneous, with lack or
loss of response being a persistent issue in up to 30% of patients,
in addition to potential side-effect, such as infections and allergic
reactions4. Variability of response and treatment failure results in
treatment switching, which in turn increases both patients’ dis-
satisfaction and costs for healthcare providers. Thus, psoriasis
could greatly profit from the implementation of stratified medi-
cine approaches to benefit patients and reduce costs5. The choice
of which biologic to prescribe is currently based on clinical fac-
tors, for example, anti-TNF are preferentially prescribed to
patients with concomitant psoriatic arthritis6. The PSORT con-
sortium, a partnership involving clinicians, translational
researchers, industry and patient groups, aims to identify deter-
minants of response to biologic therapies, and ultimately deliver a
patient stratifier to guide psoriasis management7. The analysis of
demographic, social, clinical, pharmacological and genomic data
has identified a number of factors, such as ethnicity, weight,
smoking, disease severity8, serum drug levels9 and HLA-Cw0602
status10, which are associated with outcome to biologics. How-
ever, the small effect size suggests that these factors alone are
insufficient to inform optimal treatment selection. Thus, there is
an unmet clinical need to identify biomarkers predictive of
response to biologics. In particular, biomarkers involved in dis-
ease pathogenesis and/or drug mechanism of action (i.e.
mechanistic biomarkers) are considered more informative, robust
and actionable than biomarkers simply reflecting the clinical
outcome11.
Anti-TNF inhibitors were the first class of biologics approved
for psoriasis, in line with the pleiotropic role of TNF in inflam-
mation. Activation of the transcription factor nuclear factor-κB
(NF-κB) is a key event downstream TNF signalling, inducing the
expression of inflammatory and anti-apoptotic genes, which
influence critical cellular behaviours such as activation, matura-
tion, migration, proliferation and survival12. Adalimumab is a
recombinant, fully humanized, IgG antibody with high affinity
and specificity for both soluble and membrane-bound TNF. In
clinical trials, 71% of patients with moderate-to-severe psoriasis
achieved a 75% reduction in the standard objective disease
severity score used in psoriasis—Psoriasis Area and Severity
Index (PASI; PASI75 response) after 16 weeks of adalimumab
treatment, with 45% achieving 90% reduction (PASI90
response)13. Whilst newer biologics have been developed and
licensed, adalimumab remains a first-line intervention in psor-
iasis, given its effectiveness and well-established safety profile and
—with the advent of biosimilars—significantly reduced costs.
Nevertheless, the cellular and molecular mechanisms under-
pinning its clinical efficacy are ill understood. In a small early
study, adalimumab induced normalization of keratinocyte dif-
ferentiation and decreased the number of T cells and DC in
psoriasis skin lesions14, in keeping with the down-modulation of
myeloid and Th17-response genes observed in patients treated
with etanercept15,16. Little is known about the effect of
adalimumab on circulating blood immune cells in psoriasis. In
particular, the effect of TNF-neutralization on proximal signalling
events, such as NF-κB activation, has not been investigated
thus far.
Here, as a fundamental step to identify mechanistic immune
mediators of response to adalimumab and evaluate their value as
predictive biomarkers, we investigate the blood cellular target(s)
and molecular effect of adalimumab in psoriasis. We utilise the
clinical psoriasis bioresource of the PSORT Consortium7 and
perform in-depth functional and phenotypic immunomonitoring
of blood immune cells of 67 patients with psoriasis and 20 healthy
controls, before and during biologic therapy. We validate our
findings with mechanistic in vitro experiments and skin in situ
imaging studies. Finally, we compare the predictive value of the
most promising immune traits identified and validate an immune
biomarker predictive of response in an independent patient
cohort.
Results
Adalimumab blocks NF-κB translocation in lymphoid cells. To
obtain insights into the cellular target and effect of adalimumab in
blood we monitored NF-κB activation in 16 patients undergoing
adalimumab treatment (PSORT adalimumab discovery cohort,
Supplementary Fig. 1, Supplementary Data 1), measuring NF-κB
nuclear translocation in seven major immune cell populations by
imaging flow cytometry. Fresh whole blood, obtained at baseline
before starting therapy (week 0, w0) and at week 1 (w1), 4 (w4)
and 12 (w12) after the initiation of the treatment, was stimulated
with either TNF or LPS (as additional well-known NF-κB-indu-
cer) or left unstimulated, and NF-κB nuclear translocation was
quantified as Rd score (Eq. (1) see methods) in neutrophils,
monocytes, DC, natural killer (NK), NKT, CD4+ and CD8+
T cells (Fig. 1a and Supplementary Fig. 2). Psoriasis patients
receiving the anti-12/23p40 mAb ustekinumab (n= 24) and
matched healthy volunteers (n= 11) were used as control groups
(Supplementary Fig. 1). No difference in NF-κB constitutive
nuclear localization, that is, in absence of stimulation, was
observed at any time point in any cell type (Supplementary
Fig. 3a). Following stimulation, TNF induced NF-κB transloca-
tion in both lymphoid and myeloid cells, while, as expected, LPS
only activated neutrophils, monocytes and DC in blood collected
at w0 (Fig. 1b, c). A similar activation profile was observed in the
whole blood of healthy volunteers (Supplementary Fig. 3b). NF-
κB activation induced by TNF in lymphoid cells was strongly
inhibited in the blood of patients receiving adalimumab at w1, w4
and w12 of treatment (Fig. 1b, c), but not in those receiving
ustekinumab (Supplementary Fig. 3c), in line with the molecular
pathway targeted by each drug. Adalimumab exerted the stron-
gest inhibitory effect in lymphoid cells, i.e., CD4+ T, CD8+ T, NK
and NKT cells, where NF-κB translocation was significantly
inhibited by 70–96% (Fig. 1b,c and Supplementary Data 2). In
contrast, adalimumab therapy resulted in a weaker inhibition in
myeloid cells, with only partial inhibition in DC (w1, 50%,
FDR= 0.0061; w4, 50%, FDR= 0.0066; w12, 70%, FDR =
0.0086), and no effect in monocytes and neutrophils (Fig. 1b, c,
and Supplementary Data 2). To confirm this inhibition pattern,
we stimulated whole blood obtained from healthy volunteers
(n= 3) with increasing concentration of TNF, in the presence or
absence of adalimumab added to the culture. In keeping with the
results obtained in patients undergoing adalimumab therapy,
TNF-induced NF-κB nuclear translocation was significantly
inhibited by up to 98% in T, NK and NKT cells, but only partially
in DC (70.48%, FDR= 0.084) with no effect on neutrophils and
monocytes (Supplementary Fig. 3d). As expected, neither adali-
mumab nor ustekinumab therapy had any effect on LPS-induced
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NF-κB translocation in psoriasis patients (Fig. 1b, c; Supple-
mentary Fig. 3c and Supplementary Data 2). Thus, we concluded
that the free adalimumab present in the blood stream of patients
undergoing therapy completely blocks NF-κB signalling in T, NK
and NKT cells but only partially in DC, raising the possibility that
the incomplete inhibition observed in DC may affect clinical
outcome.
NF-κB translocation in DCs at baseline correlates with lack of
response to adalimumab. Next, we investigated whether NF-κB
nuclear translocation, induced by TNF or LPS, correlated with
clinical response to adalimumab. Response was assessed applying
either a continuous model, where the outcome is % residual
disease at week 12 measured by relative PASI (i.e. PASI at week





























Fig. 1 LPS-induced NF-κB translocation in DCs at baseline correlates with response to adalimumab. a Cartoon depicting the experimental workflow.
Whole blood from psoriasis patients collected at baseline (week0, w0) and at w1, w4 and w12 after initiation of adalimumab therapy was stimulated with
TNF, LPS or left unstimulated, stained with fluorescent antibodies and NF-κB nuclear translocation was measured in distinct cell populations identified by
imaging flow cytometry, as shown in the representative images included in the cartoon. b Representative fluorescent images of selected cell populations
stained for NF-κB (green) and nucleus (DAPI, red); their colocalization is shown in yellow. c Heatmap showing NF-κB nuclear translocation measured as Rd
score in immune cell populations (n= 13–16). d Correlation analysis between NF-κB translocation (measured as Rd score) at w0 and clinical response
expressed as percentage of residual disease at w12 (measured as relative PASI, i.e. PASI at w12/PASI at w0 X 100) in LPS-stimulated dendritic cells (DCs)
in PSORT adalimumab (n= 13) and ustekinumab cohort (n= 24). Each dot represents one patient. e Representative fluorescent image of LPS-stimulated
DCs at w0 from PASI75 adalimumab responder (R) and non-responder (NR). f Violin plot graphs of NF-κB translocation in LPS-stimulated DCs at w0
for PASI75 adalimumab and ustekinumab responders (blue, adalimumab= 8; ustekinumab= 13) and non-responders (red, adalimumab= 5;
ustekinumab= 7) **p= 0.0062. g NF-κB translocation in TNF-stimulated DCs at w0 and w12 in adalimumab PASI75 responders (n= 8) and non-
responders (n= 4). Red frame: FDR < 0.0001, orange frame: FDR < 0.001, blue frame: FDR < 0.01, green frame: FDR < 0.05 compared to week (w) 0, test.
*p= 0.039, Wilcoxon test followed by FDR (c), Wilcoxon (g) or Mann–Whitney U test (f). All tests are two-sided. Source data are provided as a Source
Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25066-9 ARTICLE
Nature Communications
standard PASI75, as well as PASI90. No correlation between
TNF-induced NF-κB nuclear translocation at any time point and
% residual disease at w12 was detected in any cell type (Supple-
mentary Data 3), despite the inhibitory effect of adalimumab in
lymphoid cells (Fig. 1c). Thus, the complete inhibition of NF-κB
signalling in T, NK and NKT cells is not likely to underpin
clinical response to adalimumab at w12. However, we found a
statistically significant correlation (r2= 0.58, p= 0.002, FDR <
0.05, linear regression t test) between LPS-induced NF-κB
translocation at w0 in DCs and % residual disease, (Fig. 1d and
Supplementary Data 3). In particular, patients with higher resi-
dual disease at w12 displayed increased NF-κB activation at
baseline. Importantly, this correlation was not observed in
ustekinumab-treated patients (Fig. 1d), indicating that NF-κB
activation in DCs is a specific marker of clinical response to
adalimumab, and implicates DC NF-κB activation in the cellular
and molecular mechanisms underlying adalimumab response.
Next, we assessed whether adalimumab serum levels9 may have
influenced the post-w0 results of the correlation analysis. Linear
regression of relative PASI on NF-kB translocation and drug
concentration simultaneously, confirms that clinical response is
not correlated with NF-kB nuclear translocation in any combi-
nation of stimulation, cell type and time point, even after
accounting for variation in drug concentration between patients
(FDR > 0.05, Supplementary Data 4). Moreover, LPS-induced
NF-κB translocation at w0 was significantly (p < 0.01,
Mann–Whitney U test) lower in DCs of patients achieving
PASI75 and PASI90 response (i.e responders, (R) than in non-
responders (NR) (Fig. 1e, f and Supplementary Fig. 3e), while no
difference was observed in the ustekinumab cohort (Fig. 1f).
Finally, TNF-induced NF-kB activation in DC at w12 was sig-
nificantly reduced by adalimumab in responders but only showed
a non-statistically significant (p= 0.12, Wilcoxon test) downward
trend in non-responders (Fig. 1g). Thus, NF-κB activation in DC
prior to therapy differs in adalimumab responders and non-
responders, and DC in non-responders may be more refractory to
the inhibitory effect of adalimumab therapy.
NF-κB phosphorylation in cDC2 at baseline correlates with
lack of response to adalimumab. The NF-κB activation cascade
includes phosphorylation of p65 NF-kB subunit, such as at
Ser529, which regulates NF-κB function17. Thus, to replicate and
refine our findings we developed a 13-colours phospho-flow
cytometry panel (Supplementary Fig. 4) to study NF-κB phos-
phorylation in 11 cell subsets within cryopreserved PBMCs of
patients receiving adalimumab. The use of cryopreserved PBMCs
allowed us to extend our overall sample size up to 43 patients
(PSORT adalimumab combined cohort, Supplementary Fig. 1;
Supplementary Data 1, see also “Methods”). PBMCs were sti-
mulated with LPS or TNF and phopho-p65 was measured as log10
fold change (FC) median fluorescence intensity (MFI) in CD4+
T cells, CD8+ T cells, NK, NKT cells, CD14+ monocytes, CD16+
monocytes, intermediate monocytes, plasmacytoid dendritic cells,
CD141+ type 1 conventional DC (cDC1), CD1c+ type 2 con-
ventional DC (cDC2) and double negative DC (dnDC) (Fig. 2a).
In keeping with the assay being performed in isolated PBMCS
rather than in whole blood, and thus in absence of free adali-
mumab in the blood, we did not detect any inhibitory effect of
adalimumab on TNF-induced NF-κB phosphorylation during
therapy, in neither lymphoid or myeloid cells in the PSORT
adalimumab combined cohort (n= 43) (Supplementary Fig. 5
and Supplementary Data 5). Next, we evaluated NF-κB-p65
phosphorylation in DC subsets within PBMCs of the PSORT
adalimumab discovery cohort (n= 16) previously assayed for
NF-κB nuclear translocation. In keeping with the correlation
between residual disease and NF-κB nuclear translocation in DCs
(Fig. 1d), we detected a statistically significant correlation (r2=
0.714, p= 3 × 10−4, FDR < 0.01, linear regression t test) between
LPS-induced NF-κB phosphorylation in cDC2 at baseline and
residual disease at w12 (Fig. 2b and Supplementary Data 6), thus
validating our previous finding using a different, but biologically
related, analytical read-out. Moreover, LPS-induced NF-κB
phosphorylation at w0 was significantly lower in cDC2 of PASI75
responding patients (p < 0.05, Mann–Whitney U test; Fig. 2c),
with a similar downward trend also observed in patients reaching
PASI90 (Supplementary Fig. 6a). NF-κΒ phosphorylation in
cDC2 significantly correlated with NF-κB nuclear translocation
observed in total DC of the same patients (r2= 0.586, p= 0.099,
linear regression t test; Fig. 2d), further validating cDC2 as the
main DC subset implicated in clinical response to adalimumab.
Next, we sought to replicate our findings in DCs in the PSORT
adalimumab replication cohort, (n= 27; Supplementary Fig. 1).
LPS or TNF-induced NF-κB phosphorylation in DC subsets was
correlated to clinical response at w12. We observed nominal
correlations (all linear regression t test, FDR > 0.05) between
residual disease and NF-κB phosphorylation induced by either
LPS (r2= 0.347, p= 0.0209) or TNF (r2= 0.425, p= 0.0062) in
cDC2, as well as TNF-induced NF-κb phosphorylation in pDC
(r2= 0.502, p= 0.0021) at w0 (Supplementary Fig. 6b and
Supplementary Data 6). Nevertheless, NF-κB phosphorylation
induced by LPS and TNF in cDC2, and by TNF in pDC at w0 was
significantly lower in PASI75 responders than in PASI75 non-
responders (p < 0.01, Mann–Whitney U test; Supplementary
Fig. 6c). Finally, we detected statistically significant correlations
between NF-κB phosphorylation induced by either TNF (r2=
0.285, FDR= 0.029), or LPS (r2= 0.573, FDR= 10−4) in cDC2,
as well by TNF in pDCs (r2= 0.245, FDR= 0.043) and residual
disease at w0 (all linear regression t test, Fig. 2e and
Supplementary Data 6) in the PSORT adalimumab combined
cohort (n= 43, Fig. S1). These correlations were not driven by
any clinical covariate previously associated with response to
adalimumab such as age, gender, ethnicity, smoking, weight,
psoriatic arthritis, being biologic naive, the baseline PASI or the
presence of the HLA-C*06:02 allele8,10 (Supplementary Data 7).
In keeping with the correlation analysis, NF-κB phosphorylation
at baseline was significantly lower in LPS (p < 0.0001,
Mann–Whitney U test) and TNF (p < 0.01, unpaired t test)-
stimulated cDC2 and TNF-stimulated pDC (p < 0.0001,
Mann–Whitney U test) in PASI75 responders than non-
responders (Fig. 2f–g), with a similar trend for most stimulations
for PASI90 responders and non-responders (Supplementary
Fig. 6d). Interestingly, NF-κB phosphorylation induced in PASI75
responders was the same level as HV, while it was higher in non-
responders (Supplementary Fig. 6e). The correlation between NF-
κB phosphorylation and residual disease was progressively lost in
the presence of adalimumab at w 1 and w12 (Supplementary
Data 6), albeit TNF-induced (p < 0.05, Mann–Whitney U test)
and LPS-induced (p < 0.05, Mann–Whitney U test) NF-κB
phosphorylation in cDC2 was still significantly higher in PASI75
non-responders at w1 (Supplementary Fig. 6f).
Thus, regardless of the stimulus, NF-κB activation in cDC2
before therapy plays a role in determining clinical response to
adalimumab and may have a role as a predictive biomarker of
response.
moDCs from PASI75 non-responders have increased matura-
tion at baseline. Next, we sought to gain some mechanistic
insights into the correlation between NF-κB activation in cDC2
cells and the lack of clinical response to adalimumab. It is well
established that NF-κB activation drives DC maturation through
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Fig. 2 LPS-induced NF-κB phosphorylation in cDC2 at baseline correlates with response to adalimumab. a PBMC from psoriasis patients obtained at
baseline (week 0, w0) and at w1 and w12 after starting adalimumab therapy were stimulated with either TNF or LPS and NF-κB p65 phosphorylation was
measured by phospho flow cytometry. b Correlation analysis between LPS-induced NF-κB p65 phosphorylation (log10FC) in conventional Type 2 DC
(cDC2) at w0 and clinical response, expressed as a residual disease at w12 and measured as relative PASI in the discovery cohort (n= 13). Each dot
represents one patient. c Violin plot graphs of LPS-induced NF-κB p65 phosphorylation in cDC2 at w0 in PASI75 adalimumab responders PASI (R, blue,
n= 7) and non-responders (NR, red, n= 6) *p= 0.035. d Correlation between LPS-induced NF-κB nuclear translocation in DC and LPS-induced NF-κB p65
phosphorylation in cDC2 at w0. e Correlation analyses between NF-κB p65 phosphorylation induced by different stimuli in cDC2 and plasmacytoid Dc
(pDC) and residual disease in the PSORT adalimumab combined cohort (n= 25–30). f Representative phospho flow overlay histograms of NF-κB p65
phosphorylation in DC subsets in PASI75 adalimumab responders (blue) and non-responders (red). g Violin plot graphs of NF-κB p65 phosphorylation
induced by various stimuli in DC subsets in PASI-75 adalimumab responders (blue, n= 16–20) and non-responders (red, n= 9–10) (p cDC2-
LPs= 0.00056, p cDC2-TNF= 0.013, p pDCs-TNF= 0.00034). p values and FDR are reported on the graph in (b), (d) and (e); Mann–Whitney U test
(c, g, left and right panels) or unpaired t test (g middle panel). All tests are two-sided. Source data are provided as a Source Data file.
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the expression of co-stimulatory molecules critical for T cell
priming and activation18. Thus, we hypothesized that the
increased NF-κB activation induced by inflammatory stimuli in
cDC2 in patients failing adalimumab therapy may reflect an
increased propensity to upregulate the expression of co-
stimulatory molecules.
To test our hypothesis, we generated monocyte-derived
immature DCs in vitro, as model for cDC2, using cryopreserved
baseline PBMCs of PASI75 responding and non-responding
patients (n= 17) and induced DC maturation with LPS, in the
presence or absence of adalimumab (Fig. 3a). Mature moDC of
PASI75 non-responders displayed a significantly increased
expression of CD54 (p= 0.0012, all p values are from a
Mann–Whitney U test), CD80 (p= 3.11 × 10−4), CD83
(p= 0.04) and CD86 (p= 0.0087), and an upward trend for
CD40 and HLA-DR as compared to responders, with similar
expression in responders and HV and increased level in non-
responding patients (Fig. 3b–c and Supplementary Fig. 7a). While
the addition of adalimumab significantly inhibited LPS-induced
DC maturation in the overall cohort (Supplementary Fig. 7b), as
well as in responders and non-responders (Fig. 3c), the levels of
CD54 (p= 0.009, all p values are from a Wilcoxon test), CD80
(p= 0.003) and CD86 (p= 0.02) remained significantly higher in
PASI75 non-responders as compared to responders also in
presence of adalimumab (Fig. 3b–c). moDC maturation in the
presence of adalimumab significantly reduced cell survival,
however, no difference was observed in PASI75 responding and
non-responding patients (Supplementary Fig. 7c, d). Thus, moDC
of PASI75 non-responders display an increased propensity to
upregulate co-stimulatory molecules in vitro which is not offset
by the inhibitory effect exerted by adalimumab, in line with the
effect exerted by adalimumab therapy on NF-kB translocation in
blood DC (Fig. 1g). The increased moDC maturation was
accompanied by a significant increase and an upward trend in the
production of IL12 and IL23 respectively, in the culture
supernatants of mature moDC of PASI75-non-responders, as
compared to PASI75-responders, whereas there was no difference
in the secretion of IL10, TNF, IL1β and IL6 (Supplementary
Fig. 8). Taken together, lack of clinical response to adalimumab is
associated with the intrinsic increased maturation and activation
potential of DC both in the presence and absence of the drug.
Frequency of IL-17+ T cells in the blood is associated with
response to adalimumab. DC maturation leads to T cell activa-
tion and cytokine production. Thus, we investigated whether the
increased propensity of adalimumab non-responders DCs to
upregulate co-stimulatory molecules in vitro and their resistance
to the inhibitory effect of adalimumab (Figs. 3, 1g) has an effect
on T cell responses and can be detected in circulating DCs. To
this end, we studied the phenotype of T cells and DCs in the
blood of psoriasis patients before and during adalimumab
therapy.
First, we studied circulating T cells producing the psoriasis
hallmark cytokine IL-17A alongside IL-10 producing T regulatory
(Treg) in psoriasis patients and HV (Supplementary Fig. 9). As
previously reported19, frequency of IL17A+ CD4+ T (Th17),
IL17A+ CD8+ T (Tc17) and IL-17A+ Treg cells was significantly




Adalimumab Adalimumab Adalimumab Adalimumab






























In vitro DC 
generaon
In vitro DC 
maturaon
CD54 BV510 CD80 PerCP-Cy5.5 CD83 PE CD86 BV421




10210-2 103 104 105
Fig. 3 LPS induces increased moDC maturation in adalimumab non-responders. a moDCs were generated in vitro from monocytes obtained from w0
PBMCs. Maturation was induced by adding LPS in the presence or absence of adalimumab. b Representative flow overlay histograms of maturation
markers expression in LPS-matured (filled) and LPS+ adalimumab (empty) moDCs generated in PASI75 adalimumab responders (R, blue) and non-
responders (NR, red). c Violin plot graphs of maturation markers expression (measured as log10FC MFI vs Immature DCs) in PASI-75 adalimumab
responders (blue, n= 8) and non-responders (red, n= 7). (p CD54 RvsNR= 0.0012, RvsNR A= 0.0037; # CD54= 0.0156, ## CD54= 0.0078; p CD80
RvsNR= 0.0003, RvsNR A= 0.0037; # CD80= 0.0156; p CD83 RvsNR= 0.04; # CD83 RvsR-A= 0.0156, NRvsNR-A= 0.0156; p CD86
RvsNR= 0.0022, RvsNR A= 0.02; # CD86 RvsR-A= 0.0391, NRvsNR-A= 0.0156), Mann–Whitney U test (c) between R and NR. ## p < 0.01, # p < 0.05,
Two-sided Wilcoxon matched-pair rank test for adalimumab effect. Source data are provided as a Source Data file.
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to healthy volunteers (Supplementary Fig. 10). Tc17 and IL-17A+
Treg cells significantly decreased during adalimumab therapy,
while frequency of Th17 and IL10+ Treg cells did not change
(Fig. 4a). Moreover, we detected a statistically significant
correlation (liner regression) between residual disease and the
frequency of Th17 and IL-17A+ Treg at w0 and of Tc17 at w12
(Fig. 4b and Supplementary Data 8). In keeping with this finding,
PASI75 non-responders had significantly higher frequency of
Th17 and IL-17A+ Treg at w0 and Tc17 at week 12 (Fig. 4c).































































































































































































































Fig. 4 Response to adalimumab correlates with the frequency of IL17A+ T cells and CD274 expression in DC. Immunophenotyping of PBMCs of
psoriasis patients at w0 and at w1 and w12 after starting adalimumab therapy. a Frequency of IL10+ and IL17A+ CD4, CD8 T cells and Tregs at different
time points, each line represents one patient (n= 19) (p Tc17 W0vsW1= 0.0014, W0vsW12= 3.8 × 10−6; IL17A Tregs W0vsW1= 0.045,
W0vsW12= 0.018). b Correlation analyses between the frequency of IL17A+ or IL10+ cells within CD4, CD8 or Tregs and residual disease at w12
(n= 26–28). c Representative flow cytometry colour-plots (left) and violin plots graphs of the frequency of cytokine-producing cells in adalimumab PASI75
responders (R, blue, n week 0= 18, n week 12= 15) and non-responders (NR, red, n week 0= 8, n week 12= 13) (p Th17 w0= 0.0051, Tc17 w0= 0.047,
IL17A Tregs w0= 0.011, Tc17 w12= 0.0037). d Correlation analyses between the expression of CD274 at w1 and residual disease at w12 in cDC1 and
cDC2 (n= 27). e Representative histograms overlay graphs (left) and violin plots graphs (right) of CD274 expression in DC of PASI75 adalimumab
responders (blue, n= 17) and non-responders (red, n= 10) *p= 0.045, **p= 0.0058. Kruskal–Wallis with Dunn’s multiple comparisons post-test (a),
Mann–Whitney U test (c) or unpaired t test (e). All tests are two-sided. Source data are provided as a Source Data file.
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similar in HV and PASI75 responders, but significantly higher in
non-responders (Supplementary Fig. 10b). On the other hand, the
frequency of Tc17 cells at w0 was significantly higher in both
responders and NR, but decreased to HV level in PASI75
responders at w12. Thus, clinical response to adalimumab is
associated with a decrease in circulating Tc17 at week 12, in
keeping with the emerging critical role for CD8+ T cells in
psoriasis20,21. Moreover, the frequency of Th17 cells prior to
therapy may have a role as a predictive biomarker of response, in
line with the heightened NF-kB activation and maturation status
induced in DCs.
Response to adalimumab is associated with early upregulation
of CD274 in DCs. Next, we deeply phenotyped blood DC subsets
(Combined PSORT adalimumab cohort, n= 43) using a 15-colours
flow-cytometry panel comprehensive of activation (HLA-DR,
CCR7, CD40), maturation (CD80, CD83, CD86), adhesion (CD54,
CD209) and inhibitory (CD274) markers, and applied Flow self-
organizing map (SOM) unsupervised clustering analysis22,23 to
identify cell populations and DC subsets (Supplementary Fig. 11a).
The frequency of cDC1 was significantly decreased at week 12 of
adalimumab therapy, while cDC2 and pDC were unaffected (Sup-
plementary Fig. 11b) but neither of them correlated at any time
point with clinical response at week 12 (Supplementary Fig. 11c).
Overall, marker expression did not change over time (Supple-
mentary Fig. 12 and Supplementary Data 9), or correlate, at any
time point, with clinical response at week 12 (Supplementary
Data 10) or differ between PASI75 responders and non-responders
(Supplementary Data 11). Nevertheless, we detected statistically
significant correlations (linear regression) between relative PASI
and CD274 expression at week 1 in cDC1 (r2= 0.331, FDR < 0.05)
and cDC2 (r2= 0.371, FDR < 0.05) (Fig. 4d and Supplementary
Data 10) and CD274 expression in cDC1 (p < 0.05, unpaired t test)
and cDC2 (p < 0.01, unpaired t test) at week 1 was nominally dif-
ferent (FDR > 0.05) in PASI75 responders and non-responders
(Fig. 4e and Supplementary Data 11).
To explore a possible genetic influence on CD274 expression,
we mined the Genotype-Tissue Expression database (GTEX,
www.gtexportal.org) and identified rs59906468 as a strong cis
eQTL (normalized effect size= 0.26, p= 3.6 × 10−25, linear
regression t test) in whole blood, with the A allele reducing the
expression of CD274 (Supplementary Fig. 13a). We observed a
similar trend for CD274 protein expression in DC subsets at
various time points in our genotyped adalimumab cohort
(Supplementary Fig. 13b). Moreover, in an extended PSORT
genetic dataset10, several putative associations with adalimumab
response were observed in the CD274 region at both 3 and 6 m
for both PASI75 and PASI90 response outcomes (p-values from
0.10 to 8.8 × 10−6 logistic regression t test Supplementary
Fig. 13c). Bayesian colocalization analysis suggested that
rs59906468 may be a shared causal variant for both CD274
protein expression and adalimumab response, particularly
PASI90 response at 6 m (posterior probability for shared
effect= 0.66; Supplementary Fig. 13d).
Thus, deep phenotyping of blood DCs suggests that clinical
response to adalimumab is associated with early upregulation of
the inhibitory molecule CD274 in DCs, which may be genetically
driven. However, the surface phenotype of blood DCs prior to
therapy does not play a major role in determining clinical
response nor has biomarker potential.
Increased DC maturation and IL-17+ T cell activation in
psoriasis skin of non-responders at baseline. DC maturation is
triggered at sites of inflammation and mature DCs are abundant
in psoriasis lesions. Thus, the heightened NF-kB activation and
maturation propensity detected in blood DCs following ex vivo
and in vitro stimulation may have an effect on the surface phe-
noptype of skin rather than circulating DCs. To this end, we
studied the effect of adalimumab on DC, as well as, T cell phe-
notype in lesional skin sections of PASI75 responders and non-
responders at w0 and w12 (n= 20). Baseline disease severity did
not differ in responders (median PASI at w0= 12.9 ± 3.1) and
non-responders (median PASI at w0= 13.0 ± 4.7). Adalimumab
therapy significantly decreased the number of CD11c+ DC (p <
0.01, paired t test) and their expression of CD83 (p < 0.01, paired t
test), as well as the number of IL23+ (p < 0.01 Wilcoxon test) DC
in all patients at week 12 (Fig. 5a and Supplementary Fig. 14).
However, PASI75-non-responders harboured an increased
number (p < 0.05, Mann–Whitney U test) of CD11c+ DC which
had enhanced expression of CD83 (p < 0.05, unpaired t test) and
produced IL23 in greater number (p < 0.05, unpaired t test) as
compared to PASI75-responders at w0 (Fig. 5b, c), confirming a
more mature skin DC phenotype in non-responders, in line with
the DC maturation data obtained in vitro (Fig. 3). While PDL-1
expression in CD11c DC increased with therapy in the overall
cohort (Supplementary Fig. 14b), no difference was observed
between responders and non-responders at any time point
(Supplementary Fig. 14c, d). As expected, the number of
IL17+CD4+ (Th17, p < 0.01, paired t test) and IL17+CD8+ T
(Tc17, p < 0.05, paired t test) cells present in psoriatic skin at w12
(Fig. 5d) was decreased by adalimumab therapy. The number of
Th17 (p < 0.05, Mann–Whitney U test) and Tc17 (p < 0.05,
Mann–Whitney U test) cells was significantly higher in the skin of
non-responders at w0 (Fig. 5e, f). Of interest, while number of
Th17 at w12 was similar in responders and non-responders, Tc17
cells remained significantly elevated (p < 0.01, Mann–Whitney U
test) in the skin of non-responders as compared to responders
(Fig. 5e, f), in line with the association between clinical response
to adalimumab and the decrease in circulating Tc17 cells
observed in blood at w12 (Fig. 4).
NF-κB phosphorylation in cDC2 at baseline is a biomarker of
response to adalimumab. Finally, we evaluated the predictive
value for patient stratification of the 8 blood immune traits
measured at w0 or w1 which significantly correlated with clinical
response at w12 (i.e. NF-κB phosphorylation at w0 induced by
LPS in cDC2 and by TNF in pDC and cDC2; frequency of Th17,
Tc17 and IL-17+ Tregs at w0, CD274 expression at w1 in cDC1
and cDC2). We built receiver operating characteristic (ROC)
curves for the binary outcome of PASI75 responders or non-
responders at w12 for each potential biological read-out (NF-κB
phosphorylation, T cell frequency, CD274 expression) obtained in
the PSORT adalimumab combined cohort (Supplementary
Fig. 15a) and ranked them according to their area under the curve
(AUC). The top markers were: LPS-induced NF-κB phosphor-
ylation in cDC2 at w0, frequency of Th17 at w0 and expression of
CD274 in cDC2 at w1, with an AUC of 0.922, 0.840 and 0.806,
respectively (Supplementary Fig. 15a and Fig. 6a). The best per-
forming biomarker overall, NF-κB phosphorylation in cDC2 (cut-
off threshold of 0.169 log10FC) had 80% sensitivity, 88.9% spe-
cificity, 85.7% accuracy, and predictive odds ratio (Eq. (2)) of 32
(Fig. 6b). AUC did not improve when we combined LPS-induced
NF-κB phosphorylation in cDC2 with the other top signals
identified (Fig. 6c), therefore we selected this biomarker for fur-
ther investigation and validation. The psoriasis-susceptibility
HLA-C*06:02 allele has been associated with clinical response to
biologics, with carriers less likely to respond to adalimumab10.
However, the inclusion of HLA-C*06:02 genotype in our models
did not increase the predictive value of LPS-induced NF-κB
phosphorylation in cDC2 (Fig. 6d). Follow-up data for 26 of the











































































































































Fig. 5 Response to adalimumab is associated with DC and IL-17+ T cell activation. Analysis of psoriasis lesional skin of patients at baseline (w0) and
after 12 weeks (w12) of adalimumab treatment a Number of CD11c+ DCs, expression of CD83 in CD11c+ dermal dendritic cells (DC) and number of IL-
23+ CD11c+ DC per area of analysis (750 × 750 μm) at different time points. Each line represents one patient (n CD11c and CD83= 17, n IL23= 11)
(p CD11c= 0.0093, CD83= 0.0012, IL23= 0.0049). b Representative immunofluorescence images of psoriasis skin showing total number of CD11c+
DCs (top), CD83 expression in CD11c+ DC (middle) and IL23+ CD11c+DC (bottom) in PASI75 adalimumab responders (R, n= 8–10) and non-responders
(NR, n= 6–10). c Violin plot graphs of CD11c+ DC counts (top), CD83 expression in dermal DC (middle) and number of IL23+DC in adalimumab
responders (blue, n= 8–10) and non-responders (red, n= 6–10) at w0 and w12) (p CD11c= 0.043, CD83= 0.035, IL23= 0.039). d Number of IL-17A
+CD4+ Th17 and IL-17A+CD8+ Tc17 cells per area of analysis at different time points. Each line represents one patient (n Th17= 13, n Tc17= 17)
(p Th17= 0.0013, Tc17= 0.011). e Representative immunofluorescence images of psoriasis skin showing Th17 (top) and Tc17 (bottom) in adalimumab
responders (n= 8–10) and NR (n= 6–9). f Violin plot graphs of the number of Th17 and Tc17 cells in lesional skin sections of in adalimumab responders
(blue, n Th17 week 0= 9, n Th17 week 12= 8, n Tc17 week 0= 10, n Tc17 week 12= 9) and non-responders (red, n Th17 week 0= 9, n Th17 week 12= 6, n
Tc17 week 0= 9, n Tc17 week 12= 8) at w0 and w12 (p Th17= 0.04, Tc17 w0= 0.028, Tc17 w12= 0.0037). Wilcoxon test (a bottom panel), or paired t
test (a except bottom panel, d), Mann–Whitney U test (c top panel, f) or unpaired t test (c except top panel). All tests are two-sided. Scale bars in (b, e):
100 µm (overview) and 25 µm (insets). Source data are provided as a Source Data file.
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28 patients assessed at w12, showed that LPS-induced NF-κB
phosphorylation in cDC2 at w0 also predicted PASI75 response at
6 months (cut-off threshold 0.151 log10FC, 85.7% sensitivity,
73.7% specificity and AUC of 0.80 (p < 0.05, Mann–Whitney U
test) (Supplementary Fig. 15b).
Finally, we tested the ability of the model to predict clinical
response to adalimumab at w12 in a fully independent cohort of
15 psoriasis patients (clinical validation cohort, Supplementary
Fig. 1). Applying the previously determined (Fig. 6b) cut-off
threshold of 0.169 log10 FC for LPS-induced NF-κB phosphor-
ylation in cDC2, the model predicted treatment outcome to
adalimumab at w12 with 93.3% accuracy, 100% sensitivity 90.1%
specificity (Fig. 6e).
Taken together, our results clearly identify TNF-induced and
LPS-induced NF-κB phosphorylation in cDC2 dendritic cells
prior to therapy as a predictive biomarker of response to
adalimumab which may aid in patient stratification.
Discussion
Here we report the discovery and replication of an actionable,
predictive biomarker of response to the anti-TNF adalimumab in
psoriasis. NF-κB activation of blood cDC2, measured as LPS-
induced NF-κBp65 phosphorylation before therapy, correlated
with clinical outcome independently of covariates such as disease
severity, and discriminated between PASI responders and non-
responders with high sensitivity and specificity for up to
6 months after commencing therapy. Moreover, we provide some
insights into the downstream cellular and molecular events
associated with clinical response to adalimumab. The increased
induced NF-kB activation detected in non-responders before
commencing adalimumab was associated with increased DC
maturation and resistance to the inhibitory effect of adalimumab
in vitro, as well as well increased IL-17+ T cell activation in blood,
and ultimately a more mature and proinflammatory DC pheno-
type and increased number of IL-17+ T cells in the skin.
NF-κB signalling plays a critical role in inflammation and
multiple genes of this pathway are associated with psoriasis
susceptibility24. Activation of NF-κB by inflammatory stimuli,
through the engagement of TLRs and cytokine receptors, cul-
minates in the translocation of NF-κB complexes into the nucleus
and activation of gene expression. Phosphorylation of p65 NF-κB
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Fig. 6 NF-κB phosphorylation in cDC2 at baseline as biomarker of response to adalimumab. a Receiver operator characteristic (ROC) of linear models
for LPS-induced NF-κB phosphorylation in cDC2 at baseline (w0, red line), frequency of blood Th17 cells at baseline (w0, blue line) and PDL1 expression in
cDC2 at w1 (green line) predicting PASI75 outcome in adalimumab patients at week 12 (combined cohort, n= 26–28). Black dot shows the cut-off
for maximal accuracy for the best ROC curve. p values vs an AUC of 0.5 are shown on the graph. b Dot plot graph of the PSORT adalimumab combined
cohort (n= 28) classified in PASI75 responder (R, blue, n= 18) and non-responders (NR, red, n= 10) according to the cut-off for LPS-induced NF-κB
phosphorylation in cDC2 at w0. c ROC of LPS-induced NF-κB phosphorylation in cDC2 at w0 (solid red line) and combination biomarkers (LPS-NF-kB-
cDC2 + Th17, dotted blue line; LPS-NF-kB-cDC2 + CD274-cDC2 dotted green line, and LPS-NF-kB-cDC2 + Th17 + CD274-DC2, dotted purple line). The
purple line partially overlaps with the blue line. p values vs AUC of LPS-NF-kB-cDC2 are shown. d ROC analysis for LPS-NF-kB-cDC2 predicting PASI75
outcome in adalimumab patients (solid red line) and when combined with HLA-C*06:02 genotype (dotted brown). p value vs AUC of LPS-NF-kB-cDC2 is
shown. e ROC clinical validation using optimal cut-off for LPS-induced NF-κB phosphorylation in cDC2 at w0 identified in the PSORT combined cohort to
classify an independent cohort of adalimumab patients in PASI75 responders (blue, n= 11) and non-responders (red, n= 4) (clinical validation cohort).
Two-tailed Mann–Whitney U test, (a, c, d). Source data are provided as a Source Data file.
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function by increasing its transcriptional activity17. We show that
ex vivo TNF-induced NF-κB translocation was largely inhibited
in most immune cell types by the free drug present in the blood of
patients sampled during therapy. Nevertheless, the near-complete
inhibition of induced NF-κB signalling in T cells mediated by
adalimumab does not underpin its mechanism of action in
psoriasis as it does not correlate with clinical response. On the
other hand, TNF-induced NF-kB activation in DC was only
partially inhibited by adalimumab, with DC from non-responders
more refractory to its inhibitory effect. Moreover, NF-κB activa-
tion induced in DC by various pro-inflammatory stimuli before
commencing therapy, and measured as either nuclear transloca-
tion or p65 phosphorylation, correlated with lack of clinical
response at w12.
DC of myeloid and plasmacytoid lineage are highly implicated
in psoriasis pathogenesis, alongside T cells and keratinocytes2,3.
Mature myeloid cDC with high T-cell stimulatory capacity are
enriched in skin lesions where they produce IL-23 and other
proinflammatory cytokines25 and are poised to present putative
auto-antigens, such as LL37, to T cells. Activation of NF-κB
signalling in DC, triggered by either pathogen-associated mole-
cular patterns or proinflammatory cytokines, induces most of the
phenotypic and functional characteristics typical of mature DCs,
inducing the expression of MHC II and co-stimulatory
molecules26,27. TNF blockade by anti-TNF etanercept and
infliximab impairs maturation of DC generated in vitro from
healthy volunteers, resulting in reduced levels of HLA-DR and
co-stimulatory molecules16,28. Moreover, the expression of co-
stimulatory molecules in DCs from psoriasis skin diminished
during etanercept therapy16 and in vitro-derived DC from
rheumatoid arthritis patients receiving anti-TNF displayed
impaired upregulation of co-stimulatory molecules and poor T-
cell stimulatory activity28. Our data build on these previous
findings, validating cDC2 as the key mechanistic cellular target of
adalimumab influencing the clinical outcome. cDC2 are the
major population of myeloid cDC in human blood, produce high
levels of IL-23 and are potent activator of Th17 and CD8+
T cells29. Moreover, cDC2, but not cDC1, are largely increased in
psoriasis lesional epidermis as compared to non lesional and
healthy skin30. Thus, the biomarker potential of this specific
subset is in line with their major involvement in psoriasis.
In keeping with the increased NF-κB activation, the phenotype
of in vitro-generated DC in PASI75 non-responders before
commencing adalimumab was strikingly different from DC
generated from responders and healthy volunteers. Non-
responders DCs displayed a more mature phenotype, which
albeit inhibited by in vitro adalimumab, remained significantly
different from that of responders, suggesting that an intrinsic
increased propensity to respond to inflammatory and maturation
stimuli limits the beneficial effect of TNF-blockade. Crucially, and
despite disease severity was comparable between the two groups,
the skin of PASI75 non-responders harboured DC with a more
mature and activated phenotype before commencing the therapy,
thus validating the in vitro findings. Moreover, the lack of phe-
notypic differences in circulating blood DC prior to therapy
suggests that a pro-inflammatory environment is required to
trigger such differences, otherwise undiscernible in resting
ex vivo cells.
The significant correlation between clinical response and NF-
κBp65 phosphorylation in cDC2, induced by TNF or LPS sug-
gests a mechanistic link between DC intrinsic maturation
potential and adalimumab clinical efficacy. Not surprisingly, the
correlation with the best predictive value was detected in LPS-
stimulated cells, as LPS is more efficient than TNF to activate NF-
kB in cDC2 in our experiments and has been shown to be more
efficient at maturing DCs in vitro31. Nevertheless, LPS induces
autocrine TNF in DC32, thus providing a further potential bio-
logical rationale between the identified biomarker and the bio-
logical pathway targeted by adalimumab.
DC immunogenicity is determined both by their maturation
state and their lifespan. moDCs and blood cDC2 express both
TNF receptor (TNFR)-1 and TNFR2, withTNFR1 the major
TNFR controlling their maturation through the integrated acti-
vation of “canonical” NF-κB p65 and “non canonical” NF-κB
RelB pathway31,33. Moreover, p65 NF-κB mediates the pro-
survival effect mediated by TNFR1 in DC31. It is possible that DC
of non-responding patients may also have increased survival and
extended lifespan, as suggested by the induction of apoptosis
detected during DC maturation in the presence of in vitro TNF
blockade28. However, conflicting data have been observed in
psoriasis skin14,34. In our in vitro system, adalimumab sig-
nificantly decreased cell viability measured at day 8 of culture,
with a minimal upward trend detected in non-responding
patients. Similarly, although the overall number of CD11c+ DC
was decreased at w12, it did not discriminate between PASI75
responders and non-responders, suggesting that, although affec-
ted by TNF-blockade, DC survival is unlikely to determine clin-
ical response to adalimumab.
An intriguing possibility is that the expression of the immune
checkpoint CD274/PDL-1 may be involved in underpinning DC
as cellular determinants of response to adalimumab, as suggested
by the correlation between CD274 expression and clinical
response. Moreover, this effect may be genetically driven with at
least one eQTL possibly explaining both CD274 expression and
response to adalimumab. CD274, expressed by DC, is the main
inhibitory ligand of CD279, also known as PD-1, expressed on
T cells. Engagement of CD279 by CD274 alters T cell activity, by
inhibiting T cell proliferation, survival and cytokine production35.
CD279/PD1 is expressed on IL-17A+ T cells in psoriasis lesions
and its blockade ameliorates inflammation in the aldara-induced
psoriasiform skin inflammation model36. Another link between
CD274/PDL-1 and psoriasis stems from the clinical observation
than more than one third of cancer patients treated with Immune
checkpoint inhibitors targeting cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4), CD279/PD-1 or CD274/PD-L1
develop cutaneous immune-related adverse events (irAEs),
including characteristic psoriasis lesions37.
Early studies have investigated the effect of TNF blockade on
circulating 17A-producing T cells, with conflicting results. Two
studies reported only a modest and insignificant decrease in
frequency of circulating Th17 cells in patients receiving any of the
anti-TNF agents19,38, while another two found a significant
decrease in circulating Th17 cells in patients undergoing adali-
mumab or etanercept treatment39,40. We found that the fre-
quency of circulating Th17 cells did not change during
adalimumab treatment, while circulating Tc17 cells dramatically
decreased. More importantly, the frequency of IL17A+ T cells,
either Th, Tc or Treg, was higher in PASI75 non-responders
before commencing adalimumab, while Tc17 remained increased
in PASI7 non-responders at week 12. An association between
high baseline frequency of Th17 and lack of response to anti-
TNFs has also been reported in RA41. In keeping with our blood
data, the number of both Th17 and Tc17 cells in lesional psoriasis
skin was significantly higher in PASI75 non-responders at w0,
albeit disease severity was comparable in responders and non-
responders. Moreover, only Tc17 cells remained higher in non-
responders at w12. Thus, while the frequency of circulating
IL-17+ T cells before the start of the therapy may have a role in
determining the clinical outcome, an effective clinical response is
only achieved in the presence of a significant decrease of Tc17
cells in both blood and skin. This is in line with the retainment of
IL-17+ CD8+ Tissue-resident memory (Trm) cells in clinically
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resolved psoriasis lesion, where they are poised to be
reactivated42, and the beneficial effect of CD8 blockade in pre-
venting psoriasis development in the AGR 129 xenotransplant
model21. Tc17 could therefore play a role as a dynamic or sur-
rogate biomarker, to monitor the effect of the drug at a clinical
endpoint11, rather than a predictive one. Nevertheless, our data
show that despite the total inhibition of NF-kB signalling in
T cells exerted by adalimumab, clinical response is more likely to
be determined by its direct effect on DC, which in turn may affect
T cells in blood and skin. This may also explain the stronger
predictive value of LPS-induced NF-κB p65 phosphorylation in
cDC2 when compared to the other blood immune traits which
correlate with clinical response.
Taken together, our study uncovers key baseline determinants
of response to adalimumab in psoriasis at molecular and cellular
levels, from the more proximal signalling events, such as NF-κB
activation in cDC2, to the ultimate effect on pathogenic IL-17+
T cells in blood and skin. Adalimumab is less effective in indi-
viduals in which increased NF-κB signalling induces a heightened
maturation phenotype in DC and has increased frequency of IL-
17+ T cells in blood and skin before the start of the therapy
(Fig. 7). These findings suggest the existence of a specific disease
endotype with direct implications on clinical response to adali-
mumab. Importantly, we identified, replicated and validated LPS-
induced NF-κB p65 phosphorylation in cDC2 at baseline as a
predictive biomarker of clinical response to adalimumab. Blood
biomarkers are minimally invasive and transcription factor
phosphorylation is already a validated diagnostic tool in cancer43.
Our specific phospho-assay has already the key advantage to
being used in cryopreserved cells, thus allowing maximal flex-
ibility in terms of sample collection. Moreover, there is scope for
further development into a more clinically scalable test (e.g. using
whole blood) to be used for further clinical validation in pro-
spective clinical trials. Importantly, such trials should also address
the predictive value of the test not only for other anti-TNF agents
but particularly for their more recent cheaper biosimilars44,
providing an alternative to the more expensive biologics targeting
the IL-23/IL-17 pathway. Finally, our findings have the potential
to inform patient stratification in other immune-mediated
inflammatory diseases such as inflammatory bowel disease and
rheumatoid arthritis where TNF-blockade is also a therapeutic
cornerstone41,45.
Methods
Study design and patient cohorts. The study included 67 adult patients with
chronic plaque-type psoriasis with moderate-severe disease (PASI > 10) recruited
into the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) study7 at
six centers in the UK between May 2015 and July 2018 and due to start biologic
therapy (ustekinumab or adalimumab) as part of routine clinical practice (Sup-
plementary Data 1). Exclusion criteria were the use of systemic or biological
therapy for psoriasis for 2 weeks prior to study entry, use of PUVA therapy for
3 months or UV-B for 1 month prior to study entry or use of topical treatments to
site of biopsies (except for emollients) for 2 weeks prior to study entry, as well as
serious/uncontrolled systemic disease or medical condition. From this study
population we derived our discovery cohort of 16 patients receiving adalimumab
(PSORT adalimumab discovery cohort) and 24 patients receiving ustekinumab
(PSORT ustekinumab discovery cohort), all recruited in the Greater London area,
and our replication cohort of further 27 patients receiving adalimumab (PSORT
adalimumab replication cohort), recruited at various centers in the UK. All 43
PSORT patients receiving adalimumab are collectively referred as the PSORT
adalimumab combined cohort (28 PASI75 responders, median baseline PASI =
13.5 ± 5.4; 15 PASI75 non-responders, median baseline PASI = 14.2 ± 5.4; Sup-
plementary Fig. 1, Supplementary Data 1). Patients were largely of White European
descent, both genders were represented (29 males/14 females), age range was 22–72
years, mean 45 years.
The independent clinical validation cohort (Supplementary Fig. 1) comprises of
additional 15 psoriasis patients not receiving biological treatment at time of
sampling. This included nine patients prospectively recruited into the BIODIP
study46 to receive adalimumab, sampled at baseline (w0) before commencing
therapy, and six patients recruited into the Signature study47, who had previously
received adalimumab and had reached PASI75 at w12, but had then progressively
lost clinical response 10–41 months after starting therapy and were retrospectively
sampled 1–11 months after stopping adalimumab and before commencing
secukinumab. Thus, for the purpose of our analysis they were considered PASI75
responders at w12.
This study was performed in accordance with the declaration of Helsinki and
was approved by the London Bridge research ethics committee (REC numbers: 14/
LO/1685; 11/LO/1692; 06/Q0704/18; 13/EE/0241). All participants provided
written informed consent.




















Fig. 7 Mechanistic biomarker of response to adalimumab. Phosphorylation of p65NF-κB in conventional Type 2 dendritic cells (cDC2) before therapy is
an early predictive biomarker of response to adalimumab at week 12. NF-kB activation by TNF or TLR ligands, e.g., LPS, induces DC maturation which in turn
leads to the activation of IL-17A producing T helper (Th)17 and CD8+ T cytotoxic (Tc)17 cells. This is enhanced in PASI 75 non responder patients (PASI75
NR), as shown in the cartoon by the increased number of phosphorylation sites on NF-kB underneath the patient silhouettes, and results in increased
number of activated DC producing IL-23 in the skin and of Th17 and Tc17 in blood and skin before therapy, as compared to PASI75 responders (PASI75 R).
TNF-blockade by adalimumab reduces DC and T cell responses but they remain elevated in the blood and skin of PASI75 non-responders underpinning the
lack of clinical response.
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Samples were randomly assigned to experiment batches, unless otherwise
stated, and blinded for the person performing the experiments and the analyst
carrying manual analysis steps such as cell gating. Some samples were excluded
from the analysis following quality control (QC).
Blood samples and PBMCs isolation. Blood was collected at participating sites in
BD Vacutainer Hemogard Closure Plastic K2-Edta Tubes (BD Biosciences, CA).
For the discovery cohort, an aliquot of fresh blood was used for imaging flow
cytometry (see below). Peripheral blood mononuclear cells (PBMCs) were isolated
within 4 h of collection using Ficoll-Paque density gradient centrifugation in
Leucosep tubes (Greiner Bio-One, Austria). Cells were viably cryopreserved in
RPMI 1640 (Life Technologies, Carlsbad, Calif) supplemented with 11.25% Human
Serum Albumin (Gemini Bio-Products, West Sacramento, Calif)/10% dimethyl
sulfoxide (Sigma-Aldrich, St Louis, Mo) and stored in liquid nitrogen until used or
shipped to St John’s Institute of Dermatology. Prior to each experiment, cell count
and viability were measured with Via1-Cassette on a NucleoCounter NC-200
(Chemometec, DK).
Skin samples. Six millimetres punch lesional psoriasis skin biopsy specimens were
obtained from patients and bisected. Half was embedded in optimal cutting tem-
perature compound (OCT; VWR, PA) and stored in liquid nitrogen until frozen-
sectioned on a microtome-cryostat.
Imaging flow cytometry. Two hundred microlitres of fresh whole blood were
incubated with Fc block (BioLegend, CA) for 10 min at room temperature (RT).
Surface staining antibodies (Imaging flow cytometry panel, Supplementary Data 12
and Supplementary Fig. 2) were added and cells were stimulated with either TNF
20 ng/ml or LPS 1 μg/ml (Sigma-Aldrich, UK) or left unstimulated for 30 min at
37 °C. In some experiments, adalimumab 10 µg/ml (AbbVie, IL), which approx-
imates adalimumab plasma concentration when given 40 mg biweekly9, was added
30 min before stimulation. Erythrocytes were lysed and samples were simulta-
neously fixed with BD Phosflow Lyse/Fix Buffer (BD Biosciences, CA) for 10 min at
37 °C. Cells were spun down and intracellular staining primary rabbit NF-κB p65
(Cell Signalling, MA) (Imaging flow cytometry panel, Supplementary Data 12) was
added in permeabilization buffer (0.1% Triton X in PBS) and incubated for 20 min
at RT. Cells were washed in 2% BSA, 1 mM EDTA PBS and intracellular staining
secondary donkey anti-rabbit IgG (BioLegend, CA)(Supplementary Data 12) was
added in permeabilization buffer and incubated for 20 min at room temperature.
Samples were washed and DAPI (Invitrogen, CA) 25 ng/ml was added prior to
acquisition on an ImageStream MarkII imaging cytometer (Amnis, WA) at ×60
magnification. Gating of cell populations of interest and image analysis was per-
formed using the IDEAS software (Amnis, WA). Cell populations for which <10
cells were acquired were excluded from the analysis. Nuclear translocation was
assessed by the median internalization score feature for NF-κB signal in the nuclear
mask based on the DAPI staining, which represents constitutive nuclear localiza-
tion. The relative shift in the distribution between unstimulated versus stimulated
sample was calculated using Fisher’s Discriminant ratio (Rd score) according to the
formula:
Rd ¼ jMs Muj
σs þ σu
ð1Þ
Drug level measurements. Blood samples were collected in Serum Sep Clot
Activator Vacuette tubes (Greiner Bio-One, Austria) and centrifuged at 2000 × g
for 10 min, supernatant serum aliquots were obtained and frozen at –80 °C.
Samples were shipped to Sanquin (Amsterdam, The Netherlands) and adalimumab
concentration was measured by ELISA based on adalimumab’s ability to bind TNF.
Phospho flow cytometry. Cryopreserved PBMCs were thawed in 22 batches of
1–2 patients per experiments, with each experiment comprising all time points
(visits). Cells were rested overnight in RPMI-1640 medium supplemented with
10% heat-inactivated new-born calf serum (Life Technologies, CA) and penicillin/
streptavidin 1%. On the next day, 2 × 106 cells were stimulated with either TNF
100 ng/ml or LPS 1 μg/ml (Sigma-Aldrich, UK) for 15 min at 37 °C. When a
number of viable cells retrieved after resting was not sufficient, stimulation with
LPS was prioritized. Samples were placed on ice and surface staining antibodies in
brilliant stain buffer (BD Biosciences, CA) (Phospho Flow Cytometry panel,
Supplementary Data 12 and Supplementary Fig. 4) were added for 30 min. Sub-
sequent steps were carried out at RT. Cells were fixed with 1.5% paraformaldehyde
in deionized water (Electron Microscopy Science, PA) for 10 min, permeabilized
with Perm Buffer IV (BD Biosciences, NJ) for 20 min and stained with intracellular
PE NF-κB p-p65 (Ser529) antibody (BD Biosciences, CA) for 1 h (Supplementary
Data 12). Samples were acquired on a BD LSRFortessa. NF-kB p65 Ser529 phos-
phorylation was calculated as log10 mean fluorescence intensity (MFI) of stimulated
sample /MFI of unstimulated sample, abbreviated as log10 fold change (FC) MFI.
QC of the samples based on cell viability was carried out by building a ROC curve
to identify viability cut-off which best discriminates good quality samples, pre-set
as those with CD14+ cell frequency >5% and LPS-induced NF-κB phosphorylation
>0.2log10FC (Supplementary Fig. 16). As a result, samples with cell viability <93%
(sensitivity 90% and specificity 86%) were not included in the overall analysis.
Inter-experiment variation in terms of cell frequency and level of NF-κB phos-
phorylation was assessed by running one internal control (IC) sample in each
experiment. Inter-experiment variation for IC resulted to be minimal, while
variability among patient samples was much larger, as expected for true biological
variation (Supplementary Fig. 17).
moDC generation, maturation and phenotyping. Cryopreserved psoriasis patient
PBMCs collected at w0 were thawed in five batches of four patients per experiment.
Monocytes were isolated from PBMCs using MACS Separation Columns and
CD14 MicroBeads (Miltenyi, Germany) as described by the manufacturer, and
their purity was checked by flow cytometry (average purity >99%, Supplementary
Fig. 18). Cells were cultured in RPMI-1640 medium supplemented with 10% heat-
inactivated new-born calf serum (Life Technologies, CA), penicillin/streptavidin
1% for 6 days in the presence of IL-4 (500 U/ml) and GM-CSF (1000 U/ml)
(PeproTech, UK) to obtain monocyte-derived dendritic cells (moDC). DC
maturation was induced by adding LPS 250 ng/ml (Sigma-Aldrich, UK) in the
presence or absence of adalimumab 10 μg/ml (AbbVie, IL) on day 6 of culture. On
day 8, cells were stained with antibodies of the moDC panel (Supplementary
Data 12) in brilliant stain buffer (BD Biosciences, CA) (Supplementary Table 13)
for 30 min on ice, fixed with 1.5% paraformaldehyde (Electron Microscopy Science,
PA) for 10 min and acquired on a BD FACSCanto. Samples with viability <85%
were excluded from the analysis. Marker expression was reported as log10 MFI of
LPS-matured moDC /MFI of immature moDC, abbreviated as log10 FC MFI.
Experiments in healthy volunteers were run according to the same protocol by a
different operator at a later time. To avoid operator-depended batch effects, a
validation experiment was run with two samples each from psoriasis adalimumab
PASI75 responders, PASI75 non-responders and HV and a normalization factor
was calculated by dividing the median log10FC MFI of the psoriasis patient
experiments and the healthy volunteer experiments by the median of these groups
obtained in the validation experiment. Thus, normalized marker expression is
reported in Supplementary Fig. 7 comparing patients and HV. Cytokine levels in
day 8 moDC culture supernatant were assessed using Milliplex Map Human TH17
Magnetic Bead Panel (Merck Millipore, MA), following manufacturer’s
instructions.
T cell phenotyping. Cryopreserved PBMCs were thawed in 13 batches of 3–4
patients per experiments, with each experiment comprising w0 and w12 visits of
interest. Cells were rested overnight in RPMI-1640 medium supplemented with
10% heat-inactivated new-born calf serum (Life Technologies, CA) and penicillin/
streptavidin 1%. Next day 3 × 106 cells were stimulated with PMA (50 ng/ml,
Sigma-Aldrich, UK) and ionomycin (1 mg/ml, Sigma-Aldrich, UK), in the presence
of monensin (2 µM, Invitrogen, CA) and brefeldin A (3 µg/ml, Invitrogen, CA) for
3 h at 37 °C. Then, cells were centrifuged, resuspended in PBS and incubated with
live/dead FVS780 reagent (BD Biosciences, CA) on ice for 30 min. Cells were spun
down and stained with surface antibodies in brilliant stain buffer (BD Biosciences,
CA) of the T cell phenotyping panel (Supplementary Data 12) for 30 min on ice,
fixed and permeabilized with the Human FoxP3 Buffer Set (BD Biosciences, CA)
following manufacturer’s instructions. Intracellular antibodies were added for 1 h,
cells were washed and acquired on a BD FACSCanto. Samples with viability <85%
were excluded from the analysis. Inter-experiment variation in terms of cell fre-
quency (Supplementary Fig. 19a) and cytokine production (Supplementary
Fig. 19b) was assessed by running one IC sample in each experiment. Inter-
experiment variation for IC resulted to be minimal, while variability among patient
samples was significantly larger, as expected for true biological variation (Supple-
mentary Fig. 19).
Flow cytometry data acquisition, pre-processing and analysis. Flow and
phospho flow cytometry data were acquired using BD Standardized Application
Setup, which allows to combine data acquired in different experiments thus
minimizing batch-effects, and data were compensated using FACSDiva software.
Signal anomalies derived from abrupt changes in the flow rate, instability of signal
acquisition and/or margin events in the lower or upper limit of the dynamic range
were filtered out of individual sample fcs files with the R package flowAI48. Cells
were manually gated using Flowjo software 10.6.1. A graphic depicting the fluor-
escence distribution of all samples across all experiments for the different panels is
shown in Supplementary Fig. 20. Representative gating strategy and cell hierarchy
for each of the panel is shown in Supplementary Figs. 2, S4, S9, S18b and S21b.
Positive gating for each fluorochrome parameter was established using fluorescence
minus one (FMO) controls.
DC phenotyping, data pre-processing and unsupervised clustering. Cryopre-
served PBMCs were thawed in 10 batches of 4–5 patients per experiment, with each
experiment comprising all visits of interest. 2 × 106 cells were stained with live/dead
FVS780 reagent (BD Biosciences, CA) for 15 min at room temperature, centrifuged
and stained with antibodies of DC phenotyping panel (Supplementary Data 12) in
Brilliant Stain buffer (BD Biosciences, CA) on ice. Subsequently, cells were fixed
with 1.5% paraformaldehyde for 10 min, washed and acquired on a BD LSRFor-
tessa using BD Standardized Application Setup. Samples with viability <85% were
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excluded from further analysis. Inter-experiment variation in terms of cell fre-
quency (Supplementary Fig. 21a) was assessed by running one IC sample in each
experiment. Inter-experiment variation for IC resulted to be minimal, while
variability among patient samples was significantly larger, as expected for true
biological variation (Supplementary Fig. 21a).
Prior to further analysis,.fcs files were loaded into Flowjo, and HLA-DR+ cells
were pre-gated in order to eliminate debris, doublets and dead cells
(Supplementary Fig. 21b). Pre-gated.fcs files were imported into R and logicle
transformation was applied using the flowCore package49. Subsequently, a multi-
dimensional scaling (MDS) plot was created with R limma package including the
expression of all markers, outlier samples with MSD1 < −0.15 were identified and
excluded from further analysis (Supplementary Fig. 21c). Finally, cell populations
were identified by unsupervised clustering using FlowSOM22 and
ConsensusClusterPlus23 applied to all samples simultaneously. Briefly, a self-
organizing map (SOM) was built using the logicle-transformed expression of the
lineage markers (Lin, HLADR, CD11c, CD1c, CD141, CD123) with the BuildSOM
function, where cells were assigned according to their similarities to 100 grid points
of the SOM. Then, metaclustering of the SOM nodes was performed with the
ConsensusClusterPlus function. Finally, some metaclusters were manually merged
into the cell populations of interest according to their marker expression
(Supplementary Fig. 21d, e).
Skin immunofluorescence staining and quantification. 6 μm-thick skin sections
were fixed with 4% paraformaldehyde (Electron Microscopy Science, PA) and
incubated with Image-iT FX Signal Enhancer (Invitrogen, CA) for 30 min, to block
non-specific antibody binding sites. Next, sections were incubated at 4 °C overnight
with primary antibodies (Skin immunofluorescent staining panels, Supplementary
Data 12) in PBS buffer with 5% goat serum. Samples were washed with PBS-Tween
0.1% and incubated with secondary antibodies (Supplementary Data 12) diluted in
PBS buffer with 5% goat serum for 1 h at RT. Subsequently, sections were washed
with PBS-Tween 0.1% and streptavidin wash added for 30 min at RT. Finally,
samples were washed, and nuclear staining was performed by embedding samples
in Prolong Gold antifade reagent with DAPI (Invitrogen, CA). Stained sections
were evaluated by epifluorescence in a Nikon DS-Qi2 sCMOS Eclipse Ti-2 inverted
microscope (Nikon, JP) with a ×20 objective running NIS Elements. Image analysis
was carried out with NIS Elements software. Briefly, an area of analysis of 750 ×
750 μm was identified and a cellular mask created using bright spot detection with
growing enabled in the DAPI image. A minimum intensity threshold was estab-
lished for CD11c, CD4 or CD8 signals in order to identify the cells of interest.
Then, either fluorescence intensity was measured in the cells of interest (CD83 and
CD274) or a minimum intensity threshold was established to count the number of
double-positive cells (IL23, IL17A). A region of interest (ROI) to limit the analysis
to the dermis was added for the analysis of dermal DC.
Statistical analysis. For each experiment, data were subjected to quality control
steps which may have resulted in some datapoints to be excluded from the overall
statistical analysis for technical reasons. Specific exclusion criteria are described for
each experimental methodology under the relative paragraph.
To study the relationship between immune biomarkers and the clinical response
we modelled the latter first as a continuous variable by dividing PASI at week 12 by
PASI at baseline (week 0) and expressing it as a percentage. This variable represents
the % residual disease at week 12, e.g., a PASI75 responding patient has a residual
disease of 25%.
Correlation between NF-κB nuclear translocation/phosphorylation, frequency
of cytokine-producing T cell subset or CD274 expression, and residual disease were
assessed using univariate linear regression in R for each combination of stimulus,
cell type and timepoint. For imaging flow cytometry, when combinations of
stimulation-cell type had a Rd score lower than 0.3 at baseline (i.e. there was no
NF-κB translocation), they were was excluded from the correlation analysis.
To evaluate any potential confounding effect of adalimumab drug levels, a
linear regression was performed for each stimulation, cell type and time point (with
the exception of w0 where no drug had been administered yet) between NF-kB
translocation and relative PASI, with the drug concentration (in µg/ml) measured
at each visit added as a covariate.
For significant correlations, differences in NF-κB activation, marker expression
or frequencies/counts of immune populations between PASI75 responders and
non-responders (binary outcome) were assessed with the non-parametric
Mann–Whitney U test or the parametric unpaired t test in R (both two-sided), as
appropriate. Normality was assessed with the D’Agostino-Pearson test for groups
with more than 8 values; if the group contained fewer than 8 values a non-normal
distribution was assumed. The Benjamini–Hochberg approach (False Discovery
Rate, FDR) was used to control for multiple tests, as appropriate. For comparisons
between two-time points involving the same patient, differences were assessed with
the non-parametric Wilcoxon test or the parametric paired t test, as appropriate.
For comparisons between multiple time points involving the same patient,
differences were assessed with the Kruskal–Wallis with Dunn’s multiple
comparisons post-test.
ROC curve analysis and area under the ROC curve (AUC) comparison were
performed using the pROC R package50. For the long-term response analysis,
patients that had switched treatment due to inefficacy were considered non-
responders. Predictive odds ratio was calculated using the sensitivity and specificity
of the assay as reported in ref. 51.
DOR ¼ sensitivity ´ specificityð1 sensitivityÞ ´ ð1 specificityÞ ð2Þ
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Whole blood eQTL summary statistics for CD274 gene were downloaded from www.
gtexportal.org. All other data are provided in the article and its Supplementary files.
Summary statistics for CD274 genotype in the PSORT genetic dataset and raw.fcs files
can be obtained from the corresponding author upon reasonable request. Source data are
provided with this paper.
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